연구 및 보고서

The co‑developed oral GLP‑1/GLP‑2 dual‑action obesity candidate RPG‑102 showed higher drug exposure and comparable durability versus subcutaneous injection in early Phase 1a data.

Dong-A ST disclosed nonclinical results for its Alzheimer’s drug candidates targeting ferroptosis (DA-7505) and tau aggregation (DA-7503) at the AAIC in London.

Daewoong Pharmaceutical signed a technology transfer agreement with the Korea Research Institute of Bioscience and Biotechnology to acquire liver organoid production and drug evaluation technology, aiming to improve nonclinical toxicity assessment and reduce R&D costs.

The Gyeongbuk Pharmaceutical Association partnered with Medinfols to automate diabetes consumable prescription claims, aiming to cut pharmacy admin workload and enhance patient‑focused services.

Research shows 1 in 4 diabetics experience significant hearing decline, with those under 60 facing up to three times higher risk than non‑diabetics.

Study shows work ability and income can drop up to 15 years before dementia diagnosis, with early‑onset cases losing about 100 million KRW on average.

Research across universities in New Zealand, Australia, Switzerland and South Africa finds evening‑type individuals consume more calories at night and show higher body fat, blood glucose and lipid levels.

STP0404, an HIV‑1 treatment candidate from ST Pharm, demonstrated significant antiviral effects across all dose groups in a US Phase 2a study, prompting optimism for further development.

Insilico Medicine and China Medical System Holdings have agreed to a 12 billion‑yuan (≈$1.77 billion) partnership to co‑develop central nervous system therapies using Insilico’s PandaOmics AI platform.

Q32 Bio reported that its alopecia areata candidate bempikibart achieved clinical improvement and sustained response after treatment cessation in a Phase 2 study, with a sharp rise in the company’s share price.

A Columbia University study published in Annals of Internal Medicine found that sleeping about 78 minutes less per night for six weeks led to weight gain and reduced physical activity among adults.

A Mayo Clinic study presented at the ATS 2026 conference shows that modest daily activity, such as 3,000 steps, can improve survival among COPD patients averaging 69 years.